Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Intellia Therapeutics, Inc.
  6. News
  7. Summary
    NTLA   US45826J1051

INTELLIA THERAPEUTICS, INC.

(NTLA)
  Report
Delayed Nasdaq  -  04:00 2022-08-17 pm EDT
59.56 USD   -7.18%
08/05SECTOR UPDATE : Health Care Stocks Drifting Lower Near Friday Close
MT
08/05SECTOR UPDATE : Health Care
MT
08/05Goldman Sachs Adjusts Price Target for Intellia Therapeutics to $159 From $180, Maintains Buy Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sector Update: Health Care Stocks Edge Higher Premarket Friday

06/24/2022 | 09:13am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
EMERGENT BIOSOLUTIONS INC. -3.27% 28.43 Delayed Quote.-34.60%
GSK PLC 1.46% 1418.96 Delayed Quote.-29.52%
INTELLIA THERAPEUTICS, INC. -7.18% 59.56 Delayed Quote.-49.63%
NASDAQ COMPOSITE -1.25% 12938.12 Real-time Quote.-16.25%
REGENERON PHARMACEUTICALS, INC. -1.91% 636.34 Delayed Quote.0.76%
SANOFI 0.77% 82.3 Real-time Quote.-7.80%
All news about INTELLIA THERAPEUTICS, INC.
08/05SECTOR UPDATE : Health Care Stocks Drifting Lower Near Friday Close
MT
08/05SECTOR UPDATE : Health Care
MT
08/05Goldman Sachs Adjusts Price Target for Intellia Therapeutics to $159 From $180, Maintai..
MT
08/05Credit Suisse Raises Intellia Therapeutics' Price Target to $101 from $98, Keeps Outper..
MT
08/05Piper Sandler Adjusts Price Target on Intellia Therapeutics to $163 From $171, Reiterat..
MT
08/05Wedbush Cuts Price Target on Intellia Therapeutics to $58 From $68, After Q2 Report, Al..
MT
08/05Chardan Research Cuts Price Target on Intellia Therapeutics to $146 From $172, Citing Q..
MT
08/04INTELLIA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Conditio..
AQ
08/04Intellia Therapeutics Reports Wider Q2 Net Loss; Shares Slip
MT
08/04TRANSCRIPT : Intellia Therapeutics, Inc., Q2 2022 Earnings Call, Aug 04, 2022
CI
More news
Analyst Recommendations on INTELLIA THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 49,6 M - -
Net income 2022 -444 M - -
Net cash 2022 625 M - -
P/E ratio 2022 -10,2x
Yield 2022 -
Capitalization 4 527 M 4 527 M -
EV / Sales 2022 78,7x
EV / Sales 2023 84,3x
Nbr of Employees 485
Free-Float 90,3%
Chart INTELLIA THERAPEUTICS, INC.
Duration : Period :
Intellia Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INTELLIA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Last Close Price 59,56 $
Average target price 123,21 $
Spread / Average Target 107%
EPS Revisions
Managers and Directors
John M. Leonard President, Chief Executive Officer & Director
Glenn Goddard Treasurer, Chief Financial & Accounting Officer
Frank A. G. M. Verwiel Chairman
Laura Sepp-Lorenzino Chief Scientific Officer & Executive VP
Eliana Clark Chief Technology Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
INTELLIA THERAPEUTICS, INC.-49.63%4 527
MODERNA, INC.-37.79%65 706
IQVIA HOLDINGS INC.-13.27%45 640
LONZA GROUP AG-26.68%43 587
SEAGEN INC.10.47%31 450
ALNYLAM PHARMACEUTICALS, INC.31.58%27 384